Trial Profile
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Glioblastoma; Male breast cancer; Non-small cell lung cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Chimerix
- 21 Dec 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 25 Mar 2015 Status changed from not yet recruiting to recruiting according to an Oncoceutics media release.
- 15 Oct 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014, according to ClinicalTrials.gov record NCT02038699.